PTC Therapeutics Reports Third Quarter 2015 Financial Results, Provides Corporate Update and Reviews Key Findings from ACT DMD
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends up on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
PTC Therapeutics (PTCT) Bullish Stance Reiterated at Cowen on Strong Translarna Sales Growth
November 10, 2015 9:34 AM ESTPTC Therapeutics (NASDAQ: PTCT) reported 3Q15 EPS of $(1.27), vs consensus $(1.14). Translarna revenues were $9.8MM, a 59% QoQ growth in sales, vs consensus of $10.4MM.
Investor focus is on if FDA accepts Translarna's rolling NDA (which we think is very likely, target completion... More
PTC Therapeutics (PTCT) Misses Q3 EPS by 12c
November 9, 2015 4:49 PM ESTPTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.27), $0.12 worse than the analyst estimate of ($1.15). Revenue for the quarter came in at $9.78 million versus the consensus estimate of $9.88 million.
For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.
... More